ArticleJournal of clinical and translational research2022
Outcomes of surgical resection of super-giant (≥15 cm) hepatocellular carcinoma: Volume does matter, if not the size.
Article in Journal of clinical and translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 7 citations in OpenAlex.
- A case of giant cholangioblastic cholangiocarcinoma (12 kg) with left hepatectomy and hilar reconstruction: a surgical and pathological challenge.International journal of surgery case reports · 2026Article
- From prediction to judgment: what a five-variable nomogram teaches us about hepatocellular carcinoma.Journal of gastrointestinal oncology · 2026Article
- Surgical Resection of a Giant Hepatocellular Carcinoma in an 89-Year-Old Patient with Multiple Comorbidities: The Role of Frailty Assessment and Preoperative Optimisation-A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- The Differences in Clinical Outcomes for Unresectable Huge (≥ 10 cm) Hepatocellular Carcinoma With Portal Vein Thrombosis Treated by Two Different Radiotherapy Techniques.Cancer medicine · 2026Article
- Laparoscopic versus open hepatectomy in hepatocellular carcinoma patients with high-risk pathological features: a multicenter propensity score-matched study.Surgical endoscopy · 2026Article
- A deep learning-based clinical-radiomics model predicting the treatment response of immune checkpoint inhibitors (ICIs)-based conversion therapy in potentially convertible hepatocelluar carcinoma patients: a tumor marker prognostic study.International journal of surgery (London, England) · 2025Article
- Five-year complete remission of super-giant hepatocellular carcinoma with hepatectomy followed by sorafenib plus camrelizumab: A case report.World journal of gastrointestinal surgery · 2025Article
- Poor prognosis of hepatocellular carcinoma patients-how, why, and what?Journal of gastrointestinal oncology · 2024Article
- Improving clinical outcomes of patients with hepatocellular carcinoma: Role of antiviral therapy, conversion therapy, and palliative therapy.World journal of gastrointestinal oncology · 2024Article
- 3D laparoscopy and fluorescence imaging can improve surgical precision for hepatectomy.Hepatobiliary surgery and nutrition · 2024Article
- The successful posterior sectionectomy accompanied with caudate lobectomy for hepatocellular carcinoma located in segment 1 after LEN-TACE: a case report.Clinical journal of gastroenterology · 2024Article
- Liver resection, and technical advances to mitigate post-hepatectomy liver failure.Hepatobiliary surgery and nutrition · 2024Article
- A combined pre- and intra-operative nomogram in evaluation of degrees of liver cirrhosis predicts post-hepatectomy liver failure: a multicenter prospective study.Hepatobiliary surgery and nutrition · 2024Article
- Ectopic hepatocellular carcinoma of the right adrenal gland: a case description.Quantitative imaging in medicine and surgery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Resection for giant hepatocellular carcinoma (HCC) (≥10 cm) is deemed safe and feasible. However, a super-giant HCC (≥15 cm) poses unique technical complexity for hepatectomy with limited data suggesting feasibility and oncologic efficiency. This study aims to evaluate the short-term and long-term outcomes of hepatectomy in patients with super-giant HCC. Methods: A retrospective review was conducted on patients with super-giant HCC who underwent hepatectomy from 2011 to 2021. We report perioperative and oncologic outcomes such as length of stay (LOS), 30-day readmission, 90-day mortality, and cumulative survival rate. Results: Of the 18 patients, the median tumor diameter was 172.5 mm (range 150-250). The most common risk factor was chronic hepatitis B virus (HBV) infection ( Conclusion: Primary hepatic resection is safe in patients with super-giant HCC. However, long-term outcomes are poor, and high tumor volume may be associated with inferior oncological outcomes in HCC. Relevance for Patients: The presentation of super-giant HCCs may be asymptomatic and some patients are diagnosed late with limited treatment options. In some centers, this group of patients are denied surgical resection and recommended for only locoregional therapies like TACE. This paper demonstrates that hepatic resection is safe and may be an option in patients who present at an advanced stage with a high tumor burden.
Indexed as
Identifiers
35813892PMC9260342W4285025001What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.